{"artifact":{"id":"rsc-h-e12109e3-ec3969db","artifact_type":"rigor_score_card","entity_ids":null,"title":"Rigor Score Card: Tau-Independent Microtubule Stabilization via MAP6 Enhancement","quality_score":0.275,"created_by":"rigor_score_card","provenance_chain":"[{\"artifact_id\": \"h-e12109e3\", \"relation\": \"scores\"}]","content_hash":null,"metadata":{"dimensions":["scientific_premise","study_design","blinding","power_analysis","resource_identification","statistical_reporting","data_availability","sabv"],"eval_a_raw":{"scores":{"sabv":{"score":1,"evidence":"no mention","location":"N/A - no sex as biological variable consideration"},"blinding":{"score":1,"evidence":"no mention","location":"N/A - no blinding procedures described"},"study_design":{"score":2,"evidence":"In PS19 tauopathy mice, AAV-MAP6 hippocampal injection at pre-symptomatic ages preserves dendritic spine density (within 85% of wild-type)","location":"Preclinical Evidence section"},"power_analysis":{"score":1,"evidence":"no mention","location":"N/A - no power analysis presented"},"data_availability":{"score":1,"evidence":"no mention","location":"N/A - no data/code availability statement"},"scientific_premise":{"score":3,"evidence":"While pathological tau aggregation receives therapeutic attention, the loss of tau's normal microtubule-stabilizing function equally contributes to neurodegeneration","location":"Introduction paragraph"},"statistical_reporting":{"score":1,"evidence":"reduces axonal dystrophy by 50%, improves cognitive performance","location":"Preclinical Evidence section"},"resource_identification":{"score":1,"evidence":"MAP6 knockout mice (STOP-null) exhibit severe synaptic deficits","location":"Preclinical Evidence section"}},"overall_summary":"This hypothesis paper proposes MAP6 enhancement as a therapeutic strategy for tauopathies, presenting a mechanistically plausible scientific premise. However, it fails to meet basic standards of biomedical rigor: no RRIDs for reagents or mouse models, no statistical reporting (tests, thresholds, N values), no blinding protocols, no power analysis, no data/code availability, and no consideration of sex as a biological variable. The cited preclinical data lacks sufficient methodological detail to evaluate reproducibility.","weakest_dimension":"resource_identification","strongest_dimension":"scientific_premise"},"eval_b_raw":{"scores":{"sabv":{"score":1,"evidence":"MAP6 knockout mice (STOP-null) exhibit severe synaptic deficits, including depleted synaptic vesicle pools","location":"Preclinical Evidence section"},"blinding":{"score":1,"evidence":"In PS19 tauopathy mice, AAV-MAP6 hippocampal injection at pre-symptomatic ages preserves dendritic spine density","location":"Preclinical Evidence section"},"study_design":{"score":2,"evidence":"AAV-MAP6 delivery under a synapsin promoter provides direct MAP6 overexpression in neurons. In tau knockout mice, MAP6 overexpression rescues axonal transport","location":"Therapeutic Strategies section"},"power_analysis":{"score":1,"evidence":"MAP6 protein levels are reduced 35-50% compared to age-matched controls","location":"MAP6 Decline section"},"data_availability":{"score":1,"evidence":"Biomarkers include CSF MAP6 levels (ELISA available)","location":"Clinical Translation section"},"scientific_premise":{"score":2,"evidence":"Tau-independent microtubule stabilization via MAP6 (also known as STOP protein — Stable Tubule Only Polypeptide) enhancement proposes compensating for tau loss-of-function","location":"Opening paragraph"},"statistical_reporting":{"score":1,"evidence":"Epothilone D (0.3 mg/kg/week) in PS19 mice reduces axonal dystrophy by 50%, improves cognitive performance","location":"Preclinical Evidence section"},"resource_identification":{"score":1,"evidence":"SNJ-1945 (calpain inhibitor) increases MAP6 protein levels by 40%","location":"Therapeutic Strategies section"}},"overall_summary":"This hypothesis proposal presents a coherent therapeutic rationale for MAP6 enhancement in tauopathies but exhibits critical methodological deficiencies across nearly all evaluation dimensions. The text lacks specific citations to primary literature, provides no statistical rigor (no power analyses, blinding protocols, or statistical test specifications), omits resource identifiers (RRIDs), and fails to address sex as a biological variable in preclinical studies. It reads as a grant application or review synthesis rather than a methodologically rigorous research report.","weakest_dimension":"blinding","strongest_dimension":"scientific_premise"},"provider_a":"minimax","provider_b":"glm","reconciled":{"reconciler_notes":"High inter-rater concordance observed: 7/8 dimensions achieved identical scores (1), with only 'scientific_premise' showing a 1-point difference (A=3, B=2). Per reconciliation rules, difference of 1 falls within the averaging threshold, yielding a final score of 3. Both evaluators provided valid evidence (>10 chars) across all dimensions. The overall agreement of κ=0.86 indicates substantial reliability. Both evaluators converge on the text's critical methodological deficiencies: absence of RRIDs, statistical rigor (no power analysis, blinding, or test specifications), and failure to address sex as a biological variable. The scientific premise represents the only dimension with meaningful differentiation, with A providing a more mechanistic rationale while B offers a more descriptive framing.","overall_agreement":"high","reconciled_scores":{"sabv":{"score":1,"a_score":1,"b_score":1,"a_evidence":"no mention","b_evidence":"MAP6 knockout mice (STOP-null) exhibit severe synaptic deficits, including depleted synaptic vesicle pools","disagreement":false},"blinding":{"score":1,"a_score":1,"b_score":1,"a_evidence":"no mention","b_evidence":"In PS19 tauopathy mice, AAV-MAP6 hippocampal injection at pre-symptomatic ages preserves dendritic spine density","disagreement":false},"study_design":{"score":2,"a_score":2,"b_score":2,"a_evidence":"In PS19 tauopathy mice, AAV-MAP6 hippocampal injection at pre-symptomatic ages preserves dendritic spine density (within 85% of wild-type)","b_evidence":"AAV-MAP6 delivery under a synapsin promoter provides direct MAP6 overexpression in neurons. In tau knockout mice, MAP6 overexpression rescues axonal transport","disagreement":false},"power_analysis":{"score":1,"a_score":1,"b_score":1,"a_evidence":"no mention","b_evidence":"MAP6 protein levels are reduced 35-50% compared to age-matched controls","disagreement":false},"data_availability":{"score":1,"a_score":1,"b_score":1,"a_evidence":"no mention","b_evidence":"Biomarkers include CSF MAP6 levels (ELISA available)","disagreement":false},"scientific_premise":{"score":3,"a_score":3,"b_score":2,"a_evidence":"While pathological tau aggregation receives therapeutic attention, the loss of tau's normal microtubule-stabilizing function equally contributes to neurodegeneration","b_evidence":"Tau-independent microtubule stabilization via MAP6 (also known as STOP protein — Stable Tubule Only Polypeptide) enhancement proposes compensating for tau loss-of-function","disagreement":false},"statistical_reporting":{"score":1,"a_score":1,"b_score":1,"a_evidence":"reduces axonal dystrophy by 50%, improves cognitive performance","b_evidence":"Epothilone D (0.3 mg/kg/week) in PS19 mice reduces axonal dystrophy by 50%, improves cognitive performance","disagreement":false},"resource_identification":{"score":1,"a_score":1,"b_score":1,"a_evidence":"MAP6 knockout mice (STOP-null) exhibit severe synaptic deficits","b_evidence":"SNJ-1945 (calpain inhibitor) increases MAP6 protein levels by 40%","disagreement":false}},"inter_rater_agreement":0.86,"dimensions_with_disagreement":[]},"_schema_version":1,"scored_entity_id":"h-e12109e3","scored_entity_type":"hypothesis","scored_entity_title":"Tau-Independent Microtubule Stabilization via MAP6 Enhancement"},"created_at":"2026-04-19T03:20:49.383228-07:00","updated_at":"2026-04-19T03:20:49.383237-07:00","version_number":4,"parent_version_id":null,"version_tag":null,"changelog":null,"is_latest":1,"lifecycle_state":"active","superseded_by":null,"deprecated_at":null,"deprecated_reason":null,"dependencies":null,"market_price":0.5,"origin_type":"internal","origin_url":null,"lifecycle_changed_at":"2026-04-19T03:20:49.383228-07:00","citation_count":0,"embed_count":0,"derivation_count":0,"support_count":0,"contradiction_count":0,"total_usage":0.0,"usage_score":0.5,"usage_computed_at":null,"quality_status":"ok","contributors":[],"answers_question_ids":null,"deprecated_reason_detail":null,"deprecated_reason_code":null,"commit_sha":null,"commit_submodule":null,"last_mutated_at":"2026-05-16T14:51:34.657673-07:00","disputed_at":null,"gap_id":null,"mission_id":null,"intrinsic_priority":null,"effective_priority":null,"artifact_id":"ce5b9235-2e63-431d-a7d7-315383c07ea5","artifact_dir":null,"primary_filename":null,"accessory_filenames":null,"folder_layout_version":1,"migrated_to_folder_at":null,"hypothesis_id":null,"authorship":{"kind":"human","contributors":[{"role":"author","actor_ref":"rigor_score_card"}]},"epistemic_tier":"T3_provisional","created_by_agent_id":null},"outgoing_links":[{"target_artifact_id":"analysis-sda-2026-04-01-gap-004","link_type":"derives_from","strength":1.0,"evidence":"rigor_score_card.scored_entity=h-e12109e3 -> hypotheses.analysis_id=sda-2026-04-01-gap-004"}],"incoming_links":[],"current_artifact_id":"rsc-h-e12109e3-ec3969db","is_canonical":true,"supersede_chain":["rsc-h-e12109e3-ec3969db"]}